Brief: Transgene’s, Bioinvent’s BT-001 Achieves High Tumor Cure Rates In Preclinical Models

Transgene SA

22/06/2020 14:33

June 22 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE’S AND BIOINVENT’S BT-001 ACHIEVES OUTSTANDING
TUMOR
CURE RATES IN PRECLINICAL MODELS
    * PROOF OF CONCEPT FOR NOVEL ONCOLYTIC VIRUS WITH
DIFFERENTIATED
ANTI-CTLA4 ANTIBODY
    * SIGNIFICANT ANTITUMOR ACTIVITY OF BT-001 SEEN IN SEVERAL
IMMUNOCOMPETENT MODELS
    * TREATMENT WITH BT-001 ALSO INDUCED A SPECIFIC AND
LONG-LASTING
IMMUNE MEMORY, WHICH IS THOUGHT TO ACT ON DISTANT TUMORS AND TO
PREVENT POTENTIAL RELAPSE
    * PHASE I CLINICAL TRIAL WITH BT-001 EXPECTED TO START
BEFORE END
OF 2020

Source text for Eikon:  ID:nBw1yXZ0ya 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))